论文部分内容阅读
目的:探讨Axl及其配体Gas6在I型和II型上皮性卵巢癌中的表达及临床意义。方法:免疫组化En Vision法检测121例恶性、交界性及良性卵巢上皮性肿瘤标本中Axl和Gas6的表达。结果:II型卵巢癌中Axl的阳性表达率显著高于I型卵巢癌(73.7%vs 43.8%,P<0.01);前者Gas6的表达率也显著高于后者(89.5%vs 68.8%,P<0.05)。恶性卵巢肿瘤中Axl及Gas6的阳性表达率高于交界性及良性肿瘤(P<0.05)。上皮性卵巢癌组织中Axl和Gas6的高表达与FIGO分期、远处转移及淋巴结转移密切相关(P<0.05)。上皮性卵巢癌中Axl与Gas6的表达存在正相关性(χ2=4.033,r=0.217;P<0.05)。结论:Axl及其配体Gas6是II型卵巢癌的分子标志物,二者的高表达与卵巢肿瘤恶性程度及肿瘤转移密切相关,两者结合可用作卵巢肿瘤转移及疾病进展的预测指标。
Objective: To investigate the expression and clinical significance of Axl and its ligand Gas6 in type I and type II epithelial ovarian cancer. Methods: The immunohistochemical En Vision method was used to detect the expression of Axl and Gas6 in 121 cases of malignant, borderline and benign epithelial ovarian tumors. Results: The positive rate of Axl in type II ovarian cancer was significantly higher than that in type I ovarian cancer (73.7% vs 43.8%, P <0.01). The former Gas6 expression was also significantly higher than the latter (89.5% vs 68.8%, P <0.05). The positive rates of Axl and Gas6 in malignant ovarian tumors were higher than those in borderline and benign tumors (P <0.05). The high expression of Axl and Gas6 in epithelial ovarian cancer was closely related to the FIGO staging, distant metastasis and lymph node metastasis (P <0.05). There was a positive correlation between Axl and Gas6 expression in epithelial ovarian cancer (χ2 = 4.033, r = 0.217; P <0.05). Conclusion: Axl and its ligand Gas6 are molecular markers of type II ovarian cancer. The high expression of Axl and its ligand is closely related to the malignant degree of ovarian tumor and tumor metastasis. The combination of both can be used as a predictor of ovarian tumor metastasis and disease progression.